TULSA, Okla., Feb. 12, 2026 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have announced an investment in BioReact, an artificial intelligence and analytics platform powering modern bioprocess development and optimization. The funding will be used to accelerate go-to-market efforts and expand BioReact's product capabilities. Launched in April 2023, Hurricane Ventures invests in early-stage companies with strategic connections to the university. The fund leverages the university'

WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following U.S. Food and Drug Administration (FDA) feedback on the application review. "FDA shared that based on its review to date, the data in the NDA submission are unlikely to meet the Agency's threshold of substantial evidence of ef

Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments. Key High

SAN RAFAEL, Calif., Feb. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%. BioMarin intends to use the net proceeds from the offering of the Notes, together with borrowings under a new $2 billion senior secured term loan "B" facility (the "Term Loan B Facility") and $800 million senior s

Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $388.5 million for the full year of 2024. GAAP net income was $2.4 million, or $0.05 per fully diluted share, in the fourth quarter of 2025, versus a net loss of $(16.5) million, or $(0.39) per fully diluted share in the fourth quarter of 2024. For the full year 2025, GAAP net income was $9.8 millio

PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026. Recent Updates Revenue was $166.0 million for the fourth quarter of 2025, representing a 1% increase over the corresponding period of 2024. Revenue was $642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue

MIRAMAR, Fla., Feb. 12, 2026 /PRNewswire/ -- DifGen Pharmaceuticals, a leading US based generic pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (USFDA) for its Fluorometholone Ophthalmic Suspension, 0.1% - a complex generic formulation used to treat eye inflammation. This is only the second generic USFDA approval of this complex suspension product. "We are extremely proud that we received this first cycle approval, which marks a si

For Immediate Release: February 12, 2026 The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs. Specifically, risk statements related to cardiovascular disease, breast cancer and probable dementia were removed from the “boxed warning,” the agency’s most prominent safety-related warning. “This decision reflects our commitment to follow the

Dr. Justin Houman, MD, FACS, a board-certified urologist and fellowship-trained microsurgeon in Los Angeles, is earning national recognition for his advanced microsurgical treatment of varicoceles and chronic testicular pain. His practice serves as a Center of Excellence for patients seeking specialized care for complex spermatic cord conditions that have not responded to conventional treatments. LOS ANGELES, Feb. 12, 2026 /PRNewswire/ -- Dr. Justin Houman, founder of a leading men's health prac

Her passing underscores the urgent, preventable risk of cancer-associated blood clots — the second leading cause of death in people with cancer. Blood clots are one of the most serious and preventable complications of cancer.” — Dr. Rushad Patell, hematologist at Beth Israel Deaconess Medical Center PHILADELPHIA, PA, UNITED STATES, February 12, 2026 / EINPresswire.com / -- The National Blood Clot Alliance (NBCA) is urging patients and clinicians to recognize the life-threatening connection betwe